AIM ImmunoTech raises $4.2 million through warrant exercise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 8, 2026 8:40 AM EDTOCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM: AIM) (AIM ImmunoTech or the Company), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the Existing Warrants) to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other... More
